ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Wednesday, 18 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Glenmark Pharmaceuticals Business Update

Glenmark's affiliate IGI submitted an IND application to the US FDA for ISB 2301, an oncology drug candidate. Phase 1 trial initiation is planned for 2027.

Source

BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Glenmark Pharmaceuticals Ltd: key numbers

Share price
₹2,615.80
Market cap
₹73,824 Cr
Revenue (annual)
₹16,983 Cr
Net profit (annual)
₹1,362 Cr
P/E (TTM)
50.9×Sector 48.6×
Promoter holding
46.65%+0.00% QoQ
FII holding
21.51%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Glenmark Pharmaceuticals Ltd

All →

Other business update announcements

All →